Skip to content

Effect of Ganoderma lucidum in improving Psoriasis symptoms

Evaluation of oral administration efficacy of Ganoderma lucidum in amelioration of Psoriasis symptoms (a phase 2A clinical trial)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20160306026938N7
Enrollment
15
Registered
2021-05-08
Start date
2021-05-22
Completion date
Unknown
Last updated
2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis. Psoriasis

Interventions

Intervention group: the patient will take one oral capsule, each morning, noon and night..

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
19 Years to 59 Years

Inclusion criteria

Inclusion criteria: male or female volunteers with mild to moderate psoriasis patients between 19 and 59 years old healthy physical condition informed signature on consent form

Exclusion criteria

Exclusion criteria: having any systemic disease that affects the skin using any topical or oral product to treat psoriasis in the last 4 weeks using moisturizers during the study using and cotacting with any chemicals such as solvents during the study without informing the researchers people with cancer pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
The level of burning and itching. Timepoint: 2 and 4 weeks after receiving the medicine. Method of measurement: Asking the patient and psi score.

Secondary

MeasureTime frame
PSI score. Timepoint: At the begining of the intervention and then, 2 and 4 weeks after receiving the medicine. Method of measurement: ???? ?????? ????? ???? ? ???? ????.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahdi Vazirian

Tehran University of Medical Sciences

vazirian_m@tums.ac.ir+98 21 6412 1223

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026